在服用西尔代纳菲尔后过渡性血栓塞
Suheyla Karaduman1, Azmaeen Zarif2,3, Alesia Talpeka4
1Internal Medicine, St Mary's General Hospital, Passaic, New Jersey, USA.
BMJ case reports
|July 29, 2024
概括
一名70多岁的男子在开始服用西尔代纳菲尔后经历了血液失血. 症状在停药后消失,这表明存在潜在的联系,尽管考虑了其他因素.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
背景情况:
- 像西尔代纳菲尔这样的勃起功能障碍药物被广泛使用.
- 血,或咳出血,可以是一个严重的症状,各种原因.
- 老年患者经常有并发症和多药,使诊断复杂化.
研究的目的:
- 报告可能与西尔代纳菲尔使用相关的血栓塞病例.
- 突出考虑多种并发症的老年患者药物诱导副作用的重要性.
- 强调需要排除其他导致血栓塞的原因.
主要方法:
- 一个70多岁的男性患者的病例报告.
- 临床检查,血液检查和胸部CT扫描.
- 在停止使用西尔代纳菲尔后对症状的监测.
主要成果:
- 患者在开始服用西尔代纳菲尔三天后发生了血栓塞.
- 在体检或胸部CT时没有发现任何异常.
- 在停止使用西尔代纳菲尔后,症状自发消失.
- 同时使用抗凝剂被认为是潜在的诱导因素.
结论:
- 在某些患者中,西尔德纳菲尔可能与血液失血有关,特别是患有并发症的老年人.
- 在这个人群中,血栓塞的差异诊断包括伪血栓塞和恶性瘤.
- 仔细考虑药物的副作用和患者的并发症对于准确的诊断和管理至关重要.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
141
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
141
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
165
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
165
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
149
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
149
Pulmonary Hypertension: Classification and Pathogenesis
163
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
163
Pneumothorax-II
131
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
131
Radiological Investigation III: Pulmonary Angiogram and PET Scan
89
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
89


